These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23377200)

  • 1. Knee joint destruction driven by residual local symptoms after anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Imagama T; Tanaka H; Tokushige A; Seki K; Sumiura S; Yamamoto M; Nagahiro Y; Taguchi T
    Clin Rheumatol; 2013 Jun; 32(6):823-8. PubMed ID: 23377200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome.
    Fiehn C; Kessler S; Drexler W; Lorenz HM
    Rheumatol Int; 2009 Apr; 29(6):655-61. PubMed ID: 18998141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab.
    Kameda H; Sekiguchi N; Nagasawa H; Amano K; Takei H; Suzuki K; Nishi E; Ogawa H; Takeuchi T
    Mod Rheumatol; 2006; 16(6):381-8. PubMed ID: 17165001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Power Doppler ultrasound monitoring of response to anti-tumour necrosis factor alpha treatment in patients with rheumatoid arthritis.
    Iagnocco A; Finucci A; Ceccarelli F; Perricone C; Iorgoveanu V; Valesini G
    Rheumatology (Oxford); 2015 Oct; 54(10):1890-6. PubMed ID: 26070937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice.
    Hirata S; Li W; Kubo S; Fukuyo S; Mizuno Y; Hanami K; Sawamukai N; Yamaoka K; Saito K; Defranoux NA; Tanaka Y
    Mod Rheumatol; 2016 Nov; 26(6):850-856. PubMed ID: 26873570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
    Plant D; Ibrahim I; Lunt M; Eyre S; Flynn E; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
    Arthritis Res Ther; 2012 Oct; 14(5):R214. PubMed ID: 23039402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doppler sonographic comparative study on usefulness of synovial vascularity between knee and metacarpophalangeal joints for evaluation of articular inflammation in patients with rheumatoid arthritis treated by infliximab.
    Shio K; Homma F; Kanno Y; Yamadera Y; Ohguchi Y; Nishimaki T; Kanno T; Kasukawa R
    Mod Rheumatol; 2006; 16(4):220-5. PubMed ID: 16906371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
    Aletaha D; Smolen JS
    Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sanhuangyilong decoction plus methotrexate on tumor necrosis factor alpha and interferon gamma in serum and synovial fluid in rheumatoid arthritis patients with symptom pattern of damp heat obstruction.
    Liu D; Yan J; Yun M; Yang M; Luo Y; Zhang J; Guo M; Yang M; Yuan W; Zou W; Li H; Hu Y
    J Tradit Chin Med; 2016 Oct; 36(5):625-33. PubMed ID: 29933531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effectiveness on intra-articular and subcutaneous TNF inhibitor in rheumatoid arthritis patients.
    Zhang F; Ma C
    Clin Rheumatol; 2018 Jan; 37(1):199-204. PubMed ID: 28871338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of golimumab for preventing large joint destruction in patients with rheumatoid arthritis as determined by the ARASHI score.
    Kanbe K; Oh K; Chiba J; Inoue Y; Taguchi M; Yabuki A
    Mod Rheumatol; 2017 Nov; 27(6):938-945. PubMed ID: 28121204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Reliability of Disease Activity Score in 28 Joints-C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters: A Cross-sectional, Exploratory Study.
    Jensen Hansen IM; Asmussen Andreasen R; van Bui Hansen MN; Emamifar A
    J Clin Rheumatol; 2017 Mar; 23(2):102-106. PubMed ID: 27870649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
    Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year.
    Sano H; Arai K; Murai T; Fujisawa J; Kondo N; Netsu T; Hanyu T; Saeki T; Ito T; Endo N
    Mod Rheumatol; 2009; 19(4):390-4. PubMed ID: 19466615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prediction of response to TNF-α inhibitors treatment with use of swollen to tender joint count ratio (STR)].
    Kardas T; Majdan M; Gągoł D; Mazurek M
    Wiad Lek; 2015; 68(3):248-51. PubMed ID: 26753208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.
    Aletaha D; Wang X; Zhong S; Florentinus S; Monastiriakos K; Smolen JS
    Semin Arthritis Rheum; 2020 Apr; 50(2):276-284. PubMed ID: 31590930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.